Prevention of nodules and enhancement of antibody response to genetically engineered recombinant vaccine against Human Chorionic Gonadotropin (hCG) for contraception.
Priyanka TiwariMala SrivastavaRohini SehgalSunesh KumarAngamuthu SelvapandiyanAnupma KumariJagdish C GuptaGursaran Parshad TalwarPublished in: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception (2024)
The issue of nodule formation at the injection site can be mitigated either by administering the vaccine along with MIP intramuscularly or injecting hCG vaccine and MIP at separate intradermal sites. Thus, protein vaccine administered at a 2µg dose via the intramuscular route addresses both efficacy and safety concerns.